Literature DB >> 11167807

Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma.

C Zheng1, D Huang, L Liu, M Björkholm, G Holm, Q Yi, A Sundblad.   

Abstract

Multiple myeloma (MM) is a B-lineage malignancy with unknown aetiology. It has been considered that predisposing genetic factors might be implicated in the disease. In this study, the microsatellite polymorphism in the exon 3 of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene was analysed in patients with MM and monoclonal gammopathy of undetermined significance (MGUS), together with ethnically matched healthy controls. The results showed that frequencies of the genotype 86/86 and of the allele 86 were significantly decreased in MM and MGUS compared with matched healthy controls, indicating that the CTLA-4 microsatellite polymorphism might represent a susceptibility locus for MM and MGUS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11167807     DOI: 10.1046/j.1365-2141.2001.02552.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Cytotoxic T lymphocyte-associated antigen-4 +49A>G polymorphism and the risk of non-small cell lung cancer in a Chinese population.

Authors:  Hui-Ning Liu; Jian-Ling Su; Shao-Hui Zhou; Li-Jun Liu; Peng Qie
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Cytotoxic T lymphocyte antigen 4 (CTLA4) gene polymorphism with bladder cancer risk in North Indian population.

Authors:  Praveen Kumar Jaiswal; Vibha Singh; Rama Devi Mittal
Journal:  Mol Biol Rep       Date:  2014-01-04       Impact factor: 2.316

Review 3.  Current treatment options of T cell-associated immunotherapy in multiple myeloma.

Authors:  Hailing Liu; Yunbao Pan; Shan Meng; Wanggang Zhang; Fuling Zhou
Journal:  Clin Exp Med       Date:  2017-01-24       Impact factor: 3.984

Review 4.  Checkpoint inhibition in myeloma.

Authors:  Don M Benson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.

Authors:  Kavita V Shah; Andy J Chien; Cassian Yee; Randall T Moon
Journal:  J Invest Dermatol       Date:  2008-06-19       Impact factor: 8.551

Review 6.  Antibody-based immunotherapy for malignant glioma.

Authors:  Patrick C Gedeon; Katherine A Riccione; Peter E Fecci; John H Sampson
Journal:  Semin Oncol       Date:  2014-06-12       Impact factor: 4.929

7.  Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk.

Authors:  H Dean Hosgood; Dalsu Baris; Yawei Zhang; Sonja I Berndt; Idan Menashe; Lindsay M Morton; Kyoung-Mu Lee; Meredith Yeager; Shelia H Zahm; Stephen Chanock; Tongzhang Zheng; Qing Lan
Journal:  Leuk Res       Date:  2009-04-11       Impact factor: 3.156

8.  Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population.

Authors:  Lidia Karabon; Edyta Pawlak-Adamska; Anna Tomkiewicz; Anna Jedynak; Marek Kielbinski; Dariusz Woszczyk; Stanisław Potoczek; Anna Jonkisz; Kazimierz Kuliczkowski; Irena Frydecka
Journal:  Pathol Oncol Res       Date:  2011-07-09       Impact factor: 3.201

Review 9.  Host pathogen interactions in Helicobacter pylori related gastric cancer.

Authors:  Magdalena Chmiela; Zuzanna Karwowska; Weronika Gonciarz; Bujana Allushi; Paweł Stączek
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

10.  Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population.

Authors:  Lihong Wang; Dalin Li; Zhenkun Fu; Heng Li; Wei Jiang; Dianjun Li
Journal:  BMC Cancer       Date:  2007-09-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.